Cargando…

Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China

Mumps cases were reported frequently when a routine dose measles–mumps–rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Zhiying, Wen, Tingcui, Fang, Quanjun, Zheng, Canjie, Gong, Xiaoying, Li, Junji, Wang, Shuangqing, Xiang, Ziling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621056/
https://www.ncbi.nlm.nih.gov/pubmed/35675040
http://dx.doi.org/10.1080/21645515.2022.2086774
_version_ 1784821454029717504
author Yin, Zhiying
Wen, Tingcui
Fang, Quanjun
Zheng, Canjie
Gong, Xiaoying
Li, Junji
Wang, Shuangqing
Xiang, Ziling
author_facet Yin, Zhiying
Wen, Tingcui
Fang, Quanjun
Zheng, Canjie
Gong, Xiaoying
Li, Junji
Wang, Shuangqing
Xiang, Ziling
author_sort Yin, Zhiying
collection PubMed
description Mumps cases were reported frequently when a routine dose measles–mumps–rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006–2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.
format Online
Article
Text
id pubmed-9621056
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96210562022-11-01 Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China Yin, Zhiying Wen, Tingcui Fang, Quanjun Zheng, Canjie Gong, Xiaoying Li, Junji Wang, Shuangqing Xiang, Ziling Hum Vaccin Immunother Licensed Vaccines – Research Paper Mumps cases were reported frequently when a routine dose measles–mumps–rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006–2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated. Taylor & Francis 2022-06-08 /pmc/articles/PMC9621056/ /pubmed/35675040 http://dx.doi.org/10.1080/21645515.2022.2086774 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Licensed Vaccines – Research Paper
Yin, Zhiying
Wen, Tingcui
Fang, Quanjun
Zheng, Canjie
Gong, Xiaoying
Li, Junji
Wang, Shuangqing
Xiang, Ziling
Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title_full Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title_fullStr Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title_full_unstemmed Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title_short Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China
title_sort assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in quzhou, china
topic Licensed Vaccines – Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621056/
https://www.ncbi.nlm.nih.gov/pubmed/35675040
http://dx.doi.org/10.1080/21645515.2022.2086774
work_keys_str_mv AT yinzhiying assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT wentingcui assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT fangquanjun assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT zhengcanjie assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT gongxiaoying assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT lijunji assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT wangshuangqing assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina
AT xiangziling assessmentofmumpscontainingvaccineeffectivenessbydoseduring2006to2020inquzhouchina